Navigation Links
Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
Date:8/20/2007

GRAND RAPIDS, Mich., Aug. 20 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today said it was the only lab in the Midwest capable of testing nursing mothers for codeine risks cited in a Friday alert from the U.S. Food and Drug Administration (FDA).

Late Friday, the FDA issued an advisory noting new information about a very rare, but serious, side effect in nursing infants whose mothers are taking codeine and are also ultra-rapid metabolizers of that drug. The FDA advisory recommended physicians order a CYP2D6 genotyping test to determine how the patient will metabolize codeine in advance of its prescription.

The FDA noted that when codeine enters the body and is metabolized, it changes to morphine, which relieves pain. Many factors affect codeine metabolism, including a person's genetic make-up. Some people have a variation in a liver enzyme (CYP2D6) and may change codeine to morphine more rapidly and completely than other people. Results from the FDA-approved CYP2D6 test, available at the CMM, tell a physician how rapidly a specific patient will metabolize codeine based on a patient's genetic makeup.

"The CMM was created to offer physicians exactly this type of tool to prevent adverse drug reactions and better manage patient outcomes," said CMM Executive Director Daniel H. Farkas. "It is vital that any area physicians contemplating codeine for nursing mothers understand the critical need to complete a CYP2D6 test first in order to accurately determine how an individual's body will process that drug at different dosages."

The CMM performs the CYP2D6 test using the FDA-approved AmpliChip(R) system created by Roche Diagnostics. Using the test, physicians can have prior knowledge of how certain medications and levels of prescribed doses will affect their patient before beginning treatment.

Approximately 25 percent of all prescription drugs are metabolized by the enzymes measured by the AmpliChip(R) test. The test need only be done once in a person's lifetime to provide a permanent and critical reference capable of significantly improving care and reducing costs.

About the CMM

The Center for Molecular Medicine, a joint venture between Grand Rapids, Mich.-based Spectrum Health and Van Andel Institute (VAI), brings West Michigan a cutting-edge laboratory that will aid in early diagnoses and enhance personalized medicine. It offers 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness and other conditions at the DNA, RNA and protein levels. The Center brings new and increased opportunities for diagnostics and pharmaceutical companies to conduct trials in a world-class medical and clinical research environment. For more information, visit http://www.cmmdx.org.


'/>"/>
SOURCE The Center for Molecular Medicine

Copyright©2007 PR Newswire.

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. UW-Madison to receive $125M for bioenergy research center
3. Internet-enabled niche markets take center stage
4. TomoTherapy opens technical training center
5. Stem cell and regenerative medicine center to aid education and commerce
6. Mega-Metro Center may go beyond Chicago and Wisconsin
7. Berbee to expand at New Venture Center
8. Call centers and customer service: The good, the bad, and the clueless
9. Data centers: Buyers beware of over-hyped facilities
10. New angel capital centered on GenTel agreement with big pharma
11. Doyle proposes $2M for venture capital center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):